Browsing by Author "Yenihayat, Emel Merve"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    Conference Object
    Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish Aml Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of Hematology
    (Elsevier, 2023) Urlu, Selin Merih; Seval, Guldane Cengiz; Yucel, Elcin Erdogan; Mehtap, Ozgur; Yenihayat, Emel Merve; Polat, Merve Gokcen; Karakus, Volkan
  • Thumbnail Image
    Article
    Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results From the Turkish Society of Hematology AML Registry
    (MDPI, 2025) Karakus, Volkan; Pinar, Ibrahim Ethem; Iltar, Utku; Yenihayat, Emel Merve; Polat, Merve Gokcen; Celik, Serhat; Alacacioglu, Inci
    Background: Acute myeloid leukemia (AML) is an aggressive and biologically diverse hematologic cancer that disproportionately affects older individuals. Despite advances in molecular profiling and therapy, long-term outcomes remain unsatisfactory. This nationwide registry was established to provide real-world insights into clinical characteristics, treatment strategies, and survival among adult AML patients in Turkey. Methods: The Turkish AML Registry Project (ClinicalTrials.gov Identifier: NCT05979675) combines retrospective and prospective data from 23 tertiary hematology centers. Adult patients diagnosed between January 2008 and July 2023 were included. Baseline demographics, European LeukemiaNet (ELN) 2017 risk groups, Eastern Cooperative Oncology Group (ECOG) performance status, treatment intensity, and targeted therapy use were analyzed. Response and survival outcomes were assessed using Kaplan-Meier methods. Results: The interim dataset included 891 patients (median age 58 years, 45.5% >= 60). Intensive chemotherapy, most commonly 7 + 3, was applied in 74.1%, while 25.9% received lower-intensity regimens. Targeted agents, mainly venetoclax, were incorporated more frequently into low-intensity therapies (19.1% vs. 3.4%, p < 0.001). Complete remission occurred in 70.2% after intensive and 35.9% after low-intensity therapy, improving to 51.4% with targeted agents. Median overall survival (OS) was 27.2 months, with 1-year OS rates of 54.1%, 28.9%, and 17.6% for favorable, intermediate, and adverse ELN groups (p < 0.001). ECOG 0-1 predicted superior survival (1-year OS 70.3% vs. 47.0%). Conclusions: Nationwide real-world evidence underscores the prognostic relevance of ELN risk and functional status in AML. While intensive chemotherapy remains central, combining targeted agents with low-intensity regimens improves outcomes in less fit patients and supports personalized treatment approaches.
  • Thumbnail Image
    Conference Object
    Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey
    (CIG Media Group, Lp, 2025) Karakus, Volkan; Pinar, Ibrahim Ethem; Iltar, Utku; Yenihayat, Emel Merve; Polat, Merve Gokcen; Celik, Serhat; Demirkan, Fatih
  • Thumbnail Image
    Conference Object
    Prospective Real-World Outcomes of Acute Myeloid Leukemia
    (Elsevier, 2023) Karakus, Volkan; Iltar, Utku; Yenihayat, Emel Merve; Polat, Merve Gokcan; Celik, Serhat; Malkan, Umit Yavuz; Alacacioglu, Inci